10-Q: Establishment Labs Reports Q2 Loss Amid US Expansion

Establishment Labs Holdings Inc. reported increased revenue driven by U.S. market entry but saw wider net losses and significant cash burn in the second quarter of 2025.

Summary

• Revenue increased by 16.3% to $51.3 million for the three months ended June 30, 2025, compared to $44.1 million in the prior year period.
• For the six months ended June 30, 2025, revenue grew 14.0% to $92.7 million from $81.3 million in the same period of 2024.
• Net loss widened to $16.6 million for Q2 2025, compared to $17.2 million for Q2 2024, and to $37.3 million for the six months ended June 30, 2025, from $33.4 million in the prior year period.
• Gross margin improved to 68.8% for Q2 2025, up from 65.6% in Q2 2024, primarily due to higher selling prices in the United States.
• Operating expenses increased significantly, with Sales, General and Administrative (SG&A) expenses rising 34.8% in Q2 2025 to $44.2 million, and 36.0% for the six months to $83.9 million.
• Research and Development (R&D) expenses decreased slightly in Q2 2025 but increased 5.1% for the six months to $10.3 million.
• Cash and cash equivalents decreased to $54.6 million as of June 30, 2025, from $90.3 million at December 31, 2024.
• The company reported an accumulated deficit of $482.0 million as of June 30, 2025.
• U.S. sales of Motiva Implants generated $16.5 million in the first half of 2025, with over 1,000 accounts secured across the United States by June 30, 2025.
• The company launched Preserv, a minimally invasive breast tissue-preserving technology, in Brazil in February 2025, with additional launches planned globally.
• A new manufacturing facility in Costa Rica was completed in June 2024, increasing manufacturing capacity by approximately 730,000 units per year.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth and gross margin improvement, particularly in the crucial U.S. market, the significant increase in net losses and cash burn, coupled with the explicit expectation of continued losses for the foreseeable future, indicates ongoing financial challenges and high investment requirements. The extensive list of risks further highlights the speculative nature of the investment.

Positives

• Revenue increased by 16.3% in Q2 2025 and 14.0% for the first six months of 2025, demonstrating strong top-line growth.
• Gross margin improved to 68.8% in Q2 2025 and 68.1% for the six months, driven by higher selling prices in the United States market.
• Successful entry into the U.S. market following FDA approval in September 2024, with $16.5 million in U.S. sales in H1 2025 and over 1,000 accounts secured.
• Completion of a new manufacturing facility in Costa Rica significantly increases production capacity by approximately 730,000 units per year.
• Successful completion of the three-year clinical study for Mia Femtech, with the technology now offered in over 30 cities globally by more than 80 certified plastic surgeons.
• Strategic partnership with GRAMMY Award-winning singer-songwriter Meghan Trainor announced in March 2025, enhancing brand visibility.

Negatives

• Net loss widened to $16.6 million in Q2 2025 and $37.3 million for the six months ended June 30, 2025, indicating continued unprofitability.
• Operating expenses, particularly Sales, General and Administrative (SG&A), increased substantially by 34.8% in Q2 2025 and 36.0% for the six months, outpacing revenue growth.
• Cash and cash equivalents decreased significantly to $54.6 million as of June 30, 2025, from $90.3 million at December 31, 2024, reflecting high cash burn.
• Accumulated deficit grew to $482.0 million, highlighting a history of losses.
• Revenue in the Asia-Pacific market decreased by approximately 46.4% in Q2 2025 and 35.0% for the six months, primarily due to a distributor selling through existing inventory and lower consumer demand in China.
• Latin America revenue decreased by approximately 5.0% for the six months, with Brazil continuing to experience weaker underlying demand for aesthetic and reconstructive plastic surgery.

Risks

• Unfavorable global economic and political conditions, including slower growth, recession, inflation, and decreased consumer spending, could adversely affect business.
• Expectation to incur losses for the foreseeable future, with profitability dependent on the commercial success of Motiva Implants.
• Insufficient available cash resources and anticipated cash flow from operations may necessitate selling equity or convertible debt securities, or seeking other financing, potentially on unfavorable terms or causing dilution.
• Limited operating history in the United States may lead to difficulties in commercialization in competitive and rapidly evolving markets.
• Business depends on maintaining brand and customer demand; significant reduction in sentiment or demand could affect results.
• Failure to compete effectively against competitors, many of whom have greater resources, could negatively affect revenues and results.
• Any disruption at existing manufacturing facilities in Costa Rica could adversely affect business and operating results.
• Failure to maintain and develop a direct sales force in certain markets, or ineffective sales personnel, could negatively impact revenues and financial outcomes.
• Inability to educate clinicians on the safe, effective, and appropriate use of products could lead to unsatisfactory patient outcomes, negative publicity, and increased product liability claims.
• Success depends on enhancing existing products and developing new ones, which requires significant expenses and may not achieve market acceptance or regulatory approval.
• Delays or failure to obtain necessary regulatory clearances or approvals would adversely affect business growth.
• Compliance with ongoing regulatory obligations and continued regulatory review may result in significant additional expense and penalties for non-compliance.
• The medical technology industry is complex and intensely regulated; non-compliance with laws or regulations could lead to adverse outcomes.
• Reliance on a single-source, third-party supplier for medical-grade long-term implantable silicone poses risks of price increases or supply interruptions.
• Significant exposure to economic and political situations in emerging market countries could materially impact financial results.
• Pandemics, epidemics, or other public health crises may adversely affect business and financial results.
• Adverse developments affecting the financial services industry, such as liquidity issues or defaults by financial institutions, could adversely affect liquidity and financial performance.
• Fluctuations in currency rates could adversely affect results of operations, as a majority of revenues are non-U.S. dollar denominated.
• Negative publicity concerning products or competitors' products, including defects, recalls, litigation, or long-term safety impacts (e.g., BIA-ALCL, SCC), could harm reputation and reduce demand.
• The medical device industry is characterized by patent litigation, which could be costly, divert management, require damages, or prevent marketing of products.
• Inability to protect the confidentiality of trade secrets could materially adversely affect technology value and competitive position.
• Failure to obtain and maintain intellectual property protection, or insufficient patent scope, may hinder maintaining market-leading technology position.
• Information systems, or those used by third parties, may fail, be impacted by cybersecurity incidents, or suffer other attacks/damage.
• Failure to adequately protect personal information in compliance with evolving legal requirements could harm business.
• Modifications to marketed products may require new regulatory clearances or approvals, leading to delays or cessation of marketing.
• Products may cause or contribute to adverse medical events or malfunctions requiring FDA reporting, with potential sanctions for non-compliance.
• Uncertainty regarding coverage and reimbursement status of newly-approved products could limit marketability and revenue generation.
• Tax authorities may disagree with tax positions, resulting in unanticipated costs, taxes, or non-realization of expected benefits.
• Discontinuation of preferential tax treatments (e.g., Costa Rica tax holiday) or other unfavorable changes in tax law could increase compliance obligations and costs.
• Ability to use net operating losses to offset future taxable income may be subject to limitations due to ownership changes (Section 382/383).
• U.S. holders of common shares may suffer adverse tax consequences if the company is characterized as a passive foreign investment company (PFIC) or a controlled foreign corporation.
• Share price may be volatile, and purchasers could incur substantial losses due to various market and industry factors.
• Identified material weakness in internal control over financial reporting (remediated as of December 31, 2024) could recur, affecting financial reporting accuracy and timeliness.
• Rights of shareholders under British Virgin Islands law differ from U.S. law, potentially offering fewer protections.
• British Virgin Islands companies may not be able to initiate shareholder derivative actions, limiting shareholder recourse.
• British Virgin Islands law differs from U.S. law, making it difficult for U.S. investors to enforce civil liabilities against the company or its management.
• Provisions in the company's memorandum and articles of association and British Virgin Islands law could make an acquisition more difficult and prevent attempts to replace management.

Future Outlook

The company expects overall operating expenses to increase compared to 2024 due to increased commercial and operational activities following FDA approval of Motiva Implants, though management remains focused on managing these expenses. It anticipates a positive impact on gross margins in 2025 correlated with U.S. revenue growth due to higher selling prices in that region. The company expects to incur losses for the foreseeable future, particularly due to significant research and development expenses related to the IDE clinical study and a required decade-long post-approval study (PAS) for Motiva Implants in the U.S., estimated to cost between $4.0 million to $5.0 million over 10 years. Demand for products is sensitive to global and regional macroeconomic conditions, with the outlook remaining dynamic despite good performance in several regions. The company believes its available cash and cash from operations will be sufficient for liquidity requirements for at least the next 12 months but acknowledges that future capital requirements will depend on market adoption, regulatory activities, R&D costs, commercialization efforts, working capital needs, and personnel/infrastructure expansion, potentially requiring additional capital raises.

Management Comments

• "Outside the United States, we saw sequential growth in all our geographic regions in the second quarter of fiscal 2025 as compared to the first quarter."
• "Demand in fiscal 2025 improved in our EMEA markets, especially direct markets."
• "Latin America, and Brazil in particular, continues to suffer from weaker underlying demand for aesthetic and reconstructive plastic surgery; however, we are seeing stabilizing results in Brazil and continued strong growth in Argentina."
• "Our revenue in our Asia-Pacific market decreased as compared to the corresponding period of the prior year primarily due to our China distributor still selling through inventory purchased in fiscal 2024 for the commercial launch. This downturn is attributed to several factors, including lower consumer demand for aesthetic procedures."
• "Management, in collaboration with our distribution partner, is dedicated to establishing Motiva as the leading implant in China, mirroring its success in other Asian markets."
• "In the United States, we continue to see strong demand from the plastic surgeon community and positive feedback."
• "By June 30, 2025, we had successfully secured over 1,000 accounts across the United States."
• "Motiva Implants generated $16.5 million in sales within the United States in the first half of 2025."
• "The current global macroeconomic environment remains complex, with escalating trade tensions, uncertainty regarding tariffs, volatility in the capital markets, fluctuating exchange rates, declining consumer sentiment and elevated inflation and interest rates driving reductions in discretionary spending in the markets we operate."
• "Following the commercial launch of Motiva Implants in the United States in October 2024, we have been able to achieve higher selling prices for our Motiva Implants in the United States compared to other geographies and expect a positive impact on our gross margins in 2025 correlated to the U.S. revenue growth."
• "Our commercial and operational activities increased following the FDA approval of Motiva Implants. As a result, we expect overall operating expenses to increase as compared to 2024, although we remain focused on managing operating expenses."

Industry Context

The medical technology industry, particularly in aesthetic and reconstructive plastic surgery, is intensely regulated and competitive. The company's focus on innovative silicone gel-filled breast implants (Motiva Implants) positions it against major players like Mentor Worldwide (Johnson & Johnson) and Allergan (AbbVie), which have extensive clinical data and resources. The industry faces ongoing scrutiny regarding breast implant safety, including concerns about BIA-ALCL and SCC, which could reduce overall demand for silicone breast implants. The company's expansion into the U.S. market, following FDA approval, is a significant growth driver, allowing for higher selling prices compared to other geographies. However, global macroeconomic conditions, including inflation and reduced discretionary spending, continue to impact demand for elective procedures in various regions, as evidenced by declines in Asia-Pacific and Latin America.

Comparison to Industry Standards

• The company's reported low rates of adverse events (rupture, capsular contracture, safety-related reoperations) for Motiva Implants are believed to compare favorably with competitors, based on post-market surveillance data and published third-party registries.
• Competitors like Mentor Worldwide LLC (Johnson & Johnson) and Allergan plc (AbbVie Inc.) have conducted large prospective clinical studies in the U.S. starting as early as 1998-2002, using this data extensively for product promotion, which may put the company at a disadvantage despite its differentiating features.
• The company's gross margin improvement, driven by higher selling prices in the U.S. market post-FDA approval, indicates a strong value proposition or less price sensitivity in this key market compared to other geographies.
• The company's investment in a new manufacturing facility, increasing capacity by approximately 730,000 units per year, aligns with industry trends of scaling production to meet anticipated demand, similar to how larger competitors manage their supply chains.
• The company's reliance on a single-source supplier for medical-grade silicone is a common industry risk, but the filing highlights that this supplier also serves major competitors, potentially indicating a concentrated supply chain for critical raw materials across the industry.
• The company's engagement in a 10-year, 2,400-patient post-approval study (PAS) in the U.S. is a standard regulatory requirement for breast implants, comparable to the extensive post-market surveillance and data collection undertaken by established industry players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is and may become a party to various claims and lawsuits arising in the ordinary course of business, but is not a party to any material legal proceeding required to be disclosed under Item 103 of Regulation S-K.

Related Party Transactions

• Recorded revenue of $0.7 million for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of the former CEO, Juan Jos Chacn Quirs, for the six months ended June 30, 2025. Accounts receivable from this company amounted to approximately $0.5 million as of June 30, 2025.
• Paid Dr. Chacn Quirs (brother of former CEO) approximately $29,000 for training services rendered during the six months ended June 30, 2025. Accounts payable owed to Dr. Chacn Quirs amounted to approximately $70,000 as of June 30, 2025.

Stakeholder Impact

• **Shareholders:** Experience dilution from past and potential future equity raises, face continued net losses and cash burn, and are exposed to significant market and operational risks. Share price volatility is expected.
• **Employees:** The company expects to increase its workforce, particularly in manufacturing and sales/marketing, following U.S. market expansion. However, the job market in Costa Rica is competitive, posing retention challenges. Management changes may introduce uncertainty.
• **Customers (Physicians/Hospitals/Clinics):** Benefit from new product launches (Preserv) and expanded availability (Motiva Implants in U.S., Mia Femtech globally). However, potential product recalls or negative publicity could impact their practice and patient trust.
• **Suppliers:** The company's reliance on a single-source supplier for medical-grade silicone creates dependency, with potential for price increases or supply interruptions impacting manufacturing.
• **Creditors:** The company has significant outstanding debt ($221.1 million) and is subject to financial covenants, though it was in compliance as of June 30, 2025. The Inventory Funding Agreement provides additional short-term financing.

Next Steps

• Continue commercial launches of Preserv in other countries throughout 2025.
• Continue enrollment for study sites and patients in the FDA-required post-approval study (PAS) for Motiva Implants in the U.S. over the next 10 years.
• Management will continue efforts to establish Motiva as the leading implant in China in collaboration with its distribution partner.
• The company may execute additional phases of the new manufacturing facility project to further expand capacity.
• The company may elect to draw the remaining $25 million from the Tranche D Term Loan prior to December 31, 2025, upon meeting specified gross sales thresholds.

Key Dates

Recommendation

While Establishment Labs demonstrates strong revenue growth and improved gross margins, particularly driven by successful U.S. market entry, the company continues to incur substantial net losses and experience significant cash burn. This indicates a high-growth, high-investment phase with inherent risks. A 'hold' recommendation is appropriate for investors who are already positioned, acknowledging the long-term potential from market expansion and product innovation, but also the ongoing financial challenges, the need for future capital, and the extensive regulatory and competitive risks outlined in the filing. New investors should approach with caution, given the current unprofitability and cash consumption, and may wait for clearer signs of a path to sustained profitability.

Keywords

Breast Implants, Medical Devices, Aesthetic Surgery, Reconstructive Surgery, Motiva Implants, Mia Femtech, Preserv, FDA Approval, Silicone Implants, Plastic Surgery, Healthcare Technology, SEC Filing, Quarterly Report, Financial Results, Market Expansion, Manufacturing Capacity, Product Development, Regulatory Compliance, Corporate Governance